Douglas Carr sold $347 of IPSC
SVP Finance & Operations at Century Therapeutics, Inc.. 283 shares at an average of $1.23, traded Nov 4, 2024, filed Nov 5, 2024.
Score components
- +15RoleOfficer
- 0Trade size$347 at market
- 0Share of holdings soldSold 0.1% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +7.5%, 3m -40.8%, 6m -60.2%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001062993-24-018338, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 1, 2024 | FTax withholding Common Stock | -16,611 | $1.26 | $21k | 317,430 | Nov 5, 2024 |
| Nov 4, 2024 | SOpen-market sale Common Stock | -283 | $1.23 | $347 | 317,147 | Nov 5, 2024 |
Related signals
Other insiders at Century Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | Century Therapeutics, Inc. | Douglas Carr SVP Finance & Operations | $3,200 1,658 shares | -0% | |
| 23Weak | Century Therapeutics, Inc. | Gregory Russotti See Remarks | $4,993 2,587 shares | -1% | |
| 23Weak | Century Therapeutics, Inc. | Douglas Carr SVP Finance & Operations | $521 254 shares | -0% | |
| 23Weak | Century Therapeutics, Inc. | Gregory Russotti See Remarks | $1,095 534 shares | -0% | |
| 37Weak | Century Therapeutics, Inc. | Chad Cowan Chief Scientific Officer | $49k 58,060 shares | +6% | |
| 51Moderate | Century Therapeutics, Inc. | Brent Pfeiffenberger President and CEO | $30k 52,000 shares | +2% | |
| 23Weak | Century Therapeutics, Inc. | Douglas Carr SVP Finance & Operations | $137 257 shares | -0% | |
| 23Weak | Century Therapeutics, Inc. | Gregory Russotti See Remarks | $280 526 shares | -0% | |
| 23Weak | Century Therapeutics, Inc. | Chad Cowan Chief Scientific Officer | $2,736 5,462 shares | -1% | |
| 33Weak | IPSCbuy Century Therapeutics, Inc. | Brent Pfeiffenberger President and CEO | $17k 35,000 shares | +1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.